MX2020000582A - Composicion farmaceutica de anticuerpos sost y usos de la misma. - Google Patents

Composicion farmaceutica de anticuerpos sost y usos de la misma.

Info

Publication number
MX2020000582A
MX2020000582A MX2020000582A MX2020000582A MX2020000582A MX 2020000582 A MX2020000582 A MX 2020000582A MX 2020000582 A MX2020000582 A MX 2020000582A MX 2020000582 A MX2020000582 A MX 2020000582A MX 2020000582 A MX2020000582 A MX 2020000582A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
antibody pharmaceutical
sost antibody
antibody
sost
Prior art date
Application number
MX2020000582A
Other languages
English (en)
Inventor
Xun Liu
Zhen Yan
Jingjing Fang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020000582A publication Critical patent/MX2020000582A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composición farmacéutica. La composición farmacéutica comprende un anticuerpo SOST o fragmentos de unión al anticuerpo del mismo en una solución amortiguadora de ácido acético y acetato de sodio. Además, la composición farmacéutica también puede comprender azúcar, un tensioactivo no iónico u otros excipientes. Después de almacenarse durante varios meses, la composición farmacéutica muestra una buena estabilidad de anticuerpos.
MX2020000582A 2017-07-27 2018-07-26 Composicion farmaceutica de anticuerpos sost y usos de la misma. MX2020000582A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710621754 2017-07-27
PCT/CN2018/097165 WO2019020069A1 (zh) 2017-07-27 2018-07-26 一种sost抗体药物组合物及其用途

Publications (1)

Publication Number Publication Date
MX2020000582A true MX2020000582A (es) 2020-09-10

Family

ID=65040007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000582A MX2020000582A (es) 2017-07-27 2018-07-26 Composicion farmaceutica de anticuerpos sost y usos de la misma.

Country Status (13)

Country Link
US (1) US11498961B2 (es)
EP (1) EP3659586B1 (es)
JP (1) JP2020528411A (es)
KR (1) KR20200034748A (es)
CN (1) CN109952093B (es)
AU (1) AU2018305613A1 (es)
BR (1) BR112020001203A2 (es)
CA (1) CA3069392A1 (es)
MX (1) MX2020000582A (es)
TW (1) TW201909913A (es)
UA (1) UA127219C2 (es)
WO (1) WO2019020069A1 (es)
ZA (1) ZA202000238B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
WO2023098694A1 (zh) * 2021-11-30 2023-06-08 江苏恒瑞医药股份有限公司 一种抗sost抗体药物组合物及其用途
CN115181684B (zh) * 2022-04-08 2024-03-01 浙江珲达生物科技有限公司 一种mk-7的发酵培养基

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277522B1 (en) 2002-03-01 2012-11-21 UCB Manufacturing, Inc. Methods for increasing or decreasing bone density and identifying molecules
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
BRPI0809026A2 (pt) 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
WO2010100179A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
AR075715A1 (es) * 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
BR112012028920B1 (pt) * 2010-05-14 2021-03-23 Amgen Inc. Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
SG193610A1 (en) 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
RS61158B1 (sr) 2015-03-13 2021-01-29 Jiangsu Hengrui Medicine Co Anti-sklerostin antitelo, antigen vezujući fragment i njegova medicinska upotreba
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3496744A1 (en) * 2016-08-08 2019-06-19 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies

Also Published As

Publication number Publication date
CN109952093B (zh) 2022-02-08
AU2018305613A1 (en) 2020-01-30
KR20200034748A (ko) 2020-03-31
US11498961B2 (en) 2022-11-15
EP3659586A1 (en) 2020-06-03
CA3069392A1 (en) 2019-01-31
TW201909913A (zh) 2019-03-16
EP3659586A4 (en) 2020-08-12
EP3659586B1 (en) 2023-06-21
US20200199209A1 (en) 2020-06-25
CN109952093A (zh) 2019-06-28
RU2020100596A3 (es) 2021-10-13
WO2019020069A1 (zh) 2019-01-31
BR112020001203A2 (pt) 2020-07-28
UA127219C2 (uk) 2023-06-14
RU2020100596A (ru) 2021-08-27
JP2020528411A (ja) 2020-09-24
ZA202000238B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
MX2020000582A (es) Composicion farmaceutica de anticuerpos sost y usos de la misma.
AU2018267843A1 (en) PD-L1 antibody pharmaceutical composition and use thereof
EP3794037A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF
EP3762031A4 (en) ANTI-CLAUDINE ANTIBODIES 18.2 AND THEIR USES
EP3878863A4 (en) ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
WO2018109170A3 (en) Il-11ra antibodies
WO2018109174A3 (en) Il-11 antibodies
EP4039706A4 (en) ANTIBODIES TARGETING CLDN18.2, METHOD FOR PREPARATION AND USE
EP3872093A4 (en) ANTI-CLDN18.2 ANTIBODIES AND USES THEREOF
EP3992209A4 (en) CLDN18.2 ANTIBODY AND ITS USE
WO2018222722A3 (en) COMPOSITIONS COMPRISING ANTI-LAG-3 ANTIBODY OR ANTI-LAG-3 ANTIBODY AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
EP3950716A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES AND USE THEREOF
IL283754A (en) Anti-claudin antibodies, preparations containing them and their uses
MY185802A (en) Antibody formulation
EP3737421A4 (en) METHODS OF ANTIBODY DRUG CONJUGATION, PURIFICATION AND FORMULATION
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
EP3979947A4 (en) METHODS, DEVICES AND COMPOSITIONS FOR LOCAL ADMINISTRATION
IL279346A (en) Preparations containing recombinant protease inhibitors, methods for their production and uses thereof
EP4037711A4 (en) COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES
EP3911355A4 (en) RECOMBINANT LUBRICINS, COMPOSITIONS AND METHODS OF USING THE SAME
EP3856242A4 (en) ANTI-SIGLEC ANTIBODIES, PHARMACEUTICAL COMPOSITION COMPRISING IT, AND THEIR USES
EP3886921A4 (en) ACTINIUM 225 AND ACTINIUM 227 CONJUGATED ANTIBODIES, COMPOSITIONS AND METHODS RELATED
EP3846825A4 (en) FORMULATIONS AND COMPOSITIONS FOR ORTHO-AND/OR RETRO-NASAL ADMINISTRATION AND RELATED SYSTEMS, METHODS AND ITEMS
EP3782625A4 (en) AGENT TO IMPROVE CYTOKINE RELEASE SYNDROME, ETC